LB Pharmaceuticals Files Definitive Proxy Statement
Ticker: LBRX · Form: DEFA14A · Filed: Apr 23, 2026 · CIK: 0001691082
Sentiment: neutral
Topics: proxy-statement, corporate-governance
TL;DR
LB PHARMA filed proxy docs on 4/23/26. Standard stuff.
AI Summary
LB Pharmaceuticals Inc. filed a Definitive Proxy Statement (DEFA14A) on April 23, 2026. The filing concerns additional definitive proxy soliciting materials. The company's mailing and business address is 575 Madison Avenue, New York, NY 10022.
Why It Matters
This filing indicates that LB Pharmaceuticals is actively engaged in soliciting proxies, which is a crucial step in corporate governance and shareholder voting processes.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement and does not contain information that suggests immediate or significant risk.
Key Players & Entities
- LB PHARMACEUTICALS INC (company) — Filer
- 0001691082 (company) — CIK number for LB Pharmaceuticals Inc.
- 575 MADISON AVENUE NEW YORK NY 10022 (company) — Mailing and Business Address
- 2026-04-23 (date) — Filing Date
FAQ
What type of filing is this?
This is a DEFA14A filing, which is an Additional definitive proxy soliciting material.
When was this filing accepted by the SEC?
The filing was accepted on 2026-04-23 at 16:10:35.
What is the CIK number for LB Pharmaceuticals Inc.?
The CIK number for LB Pharmaceuticals Inc. is 0001691082.
What is the company's business address?
The business address is 575 Madison Avenue, New York, NY 10022.
What SIC code is associated with LB Pharmaceuticals Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 23, 2026 regarding LB PHARMACEUTICALS INC (LBRX).